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The pandemic increase in obesity is inversely associated with vitamin D levels. While a
higher BMI was causally related to lower 25-hydroxyvitamin D (25(OH)D), no evidence was
obtained for a BMI lowering effect by higher 25(OH)D. Some of the physiological functions
of 1,25(OH)2D3 (1,25-dihydroxycholecalciferol or calcitriol) via its receptor within the
adipose tissue have been investigated such as its effect on energy balance, adipogenesis,
adipokine, and cytokine secretion. Adipose tissue inflammation has been recognized as
the key component of metabolic disorders, e.g., in the metabolic syndrome. The adipose
organ secretes more than 260 different proteins/peptides. However, the molecular basis of
the interactions of 1,25(OH)2D3, vitamin D binding proteins (VDBPs) and nuclear vitamin D
receptor (VDR) after sequestration in adipose tissue and their regulations are still unclear.
1,25(OH)2D3 and its inactive metabolites are known to inhibit the formation of adipocytes
in mouse 3T3-L1 cell line. In humans, 1,25(OH)2D3 promotes preadipocyte differentiation
under cell culture conditions. Further evidence of its important functions is given by
VDR knock out (VDR−/−) and CYP27B1 knock out (CYP27B1 −/−) mouse models: Both
VDR−/− and CYP27B1−/− models are highly resistant to the diet induced weight gain,
while the specific overexpression of human VDR in adipose tissue leads to increased
adipose tissue mass. The analysis of microarray datasets from human adipocytes treated
with macrophage-secreted products up-regulated VDR and CYP27B1 genes indicating
the capacity of adipocytes to even produce active 1,25(OH)2D3. Experimental studies
demonstrate that 1,25(OH)2D3 has an active role in adipose tissue by modulating
inflammation, adipogenesis and adipocyte secretion. Yet, further in vivo studies are
needed to address the effects and the effective dosages of vitamin D in human adipose
tissue and its relevance in the associated diseases.
Keywords: 1,25-dihydroxycholecalciferol or calcitriol, vitamin D binding protein, gene regulation, adipose tissue,
adipogenesis, secretion, adipokines
Abbreviations: 25(OH)D, 25-hydroxyvitamin D; 1,25(OH)2D3, 1,25-
dihydroxycholecalciferol; VDBPs, Vitamin D binding proteins; VDR, Vitamin
D receptor; DKK1, dickkopf 1; SFRP2, Frizzled-related protein 2; BMSCs, bone
marrow stromal cells; PPARγ, peroxisome proliferator-activated receptor gamma;
RXRα, retinoid X receptor alpha; WNT10, wingless-type MMTV integration site
family member 10; C/EBP (α, β, and γ), CCAAT/enhancer-binding proteins (α,
β, and γ); ETO, C/EBPβ corepressor eight twenty-one; FABP4, fatty acid binding
protein 4; LPL, lipoprotein lipase; FASN, fatty acid synthase; SCD1, stearoyl-coA
desaturase 1; GLUT4, glucose transporter type 4; PEPCK, phosphoenolpyruvate
carboxykinase; LPS, lipopolysaccharide; TLR, toll like receptor; IL-6R, IL-6 recep-
tors; NFκB, nuclear factor kappa-B; P38MAPK, p38 mitogen-activated protein
kinase; IL-6, interleukin 6; TNF-α, tumor necrosis factor alpha; IL-1β, interleukin 1
beta; IκBα, inhibitor kappa-B; UCPs, uncoupling proteins; VDR −/−, VDR knock
out; CYP27B1−/−, CYP27B1 knock out; BMI, Body mass index; BMPs, bone
morphogenetic proteins; FGFs, fibroblast growth factors; TGFβ, transforming-
growth factor β; IGF1, insulin like growth factor 1; JAK-STAT3, janus kinase-signal
INTRODUCTION
Adipose tissue is no longer regarded as a simple storage organ
since it has been convincingly shown that it secretes more than
260 different proteins/peptides (Lehr et al., 2012). Lean people
have about 5 kg of adipose tissue, while in obese and severely
obese individuals the adipose tissue/organ could amount to 50 kg
transducer and activator of transcription 3; S6K1, ribosomal protein S6 kinase 1;
WNT, wingless family; Rb, protein of retinoblastoma family; Pref1, preadipocyte
factor 1; Necdin, melanoma-associated antigen family of proteins member;
SREBP1, sterol regulatory binding protein 1; MSCs, mesenchymal stem cells;
AP2, adipocyte-binding protein 2; MCP1, monocyte chemoattractant protein
1; CYP27B1,(25(OH)D)-1α-hydroxylase; CPTII, carnitine palmitoyltransferase
II; WAT, White adipose tissue; VDREs, vitamin D response elements; ChIP-seq,
chromatin immunoprecipitation—sequencing; LCLs, lymphoblastoid cell lines.
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or more (Frankenfield et al., 2001). Excess in adipose tissue has
been attributed to a variety of diseases including cancer, diabetes,
cardiovascular and neurodegenerative diseases and decrease in
life expectancy (Adams et al., 2006; Despres and Lemieux, 2006;
Kahn et al., 2006; Van Gaal et al., 2006). Adiposity is one of the
most serious public health problems, associated with vitamin D
insufficiency due to the decreased bioavailability of vitamin D3
(Wortsman et al., 2000). The Institute of Medicine (IOM) rec-
ommended 25-hydroxyvitamin D (25(OH)D) levels as reliable
biomarker for assessment of Vitamin D status; currently val-
ues ≤50 nmol/l or ≤20 ng/ml are considered inadequate or not
sufficient and values≥50 nmol/l or≥20 ng/ml as adequate or suf-
ficient (Ross et al., 2011) (Figure 1). 25(OH)D levels have been
determined by a variety of methods yielding different results.
The National Institutes of Health’s Office of Dietary Supplements
together with National Institute of Standards and Technology
(NIST) therefore developed a standard reference material-972
(SRM-972) for accuracy of laboratory vitamin D measurements
(Phinney et al., 2012). A recent study by the D-CarDia consor-
tium employed a Mendelian randomization (MR) approach to
establish causality and direction of the association between vita-
min D status and obesity measured by body mass index (BMI)
using information from 21 adult cohorts (up to 42,024 partici-
pants) (Vimaleswaran et al., 2013). The consortium found that
a higher BMI was causally related to lower 25(OH)D; no evi-
dence was obtained for a BMI lowering effect of higher 25(OH)D.
However, the study did not provide insights into the cellular
action of 1,25(OH)2D3 (1,25-dihydroxycholecalciferol or cal-
citriol). While the knowledge of the effects of 1,25(OH)2D3 as
an essential hormone and transcription factor is further emerg-
ing, it is increasingly acknowledged that 1,25(OH)2D3 down
regulates inflammatory responses in the adipose tissue. The
anti-inflammatory effects of 1,25(OH)2D3 might have notable
influences on population health and disease prevention, since
inflammation is thought to be the underlying cause of a range
of metabolic disorders (Hotamisligil, 2006; Huotari and Herzig,
2008; Vlasova et al., 2010).
VITAMIN D AND ADIPOGENESIS
Adipose tissue expansion is a remarkable process characterized by
the enlargement of adipocyte size known as hypertrophy and by
the increase in the number of adipocytes known as hyperplasia,
which is more strongly associated with severity of obesity (Arner
and Spalding, 2010). Both processes emerge through sequential
stages of differentiation to form mature adipocytes; this process
is called adipogenesis. Mesodermal cells are influenced by vari-
ous signals like bone morphogenetic proteins (BMPs), fibroblast
growth factors (FGFs), transforming-growth factor β(TGFβ) and
insulin like growth factor 1 (IGF1) to form preadipocytes (Lowe
et al., 2011). Furthermore, preadipocytes undergo differentiation
to mature adipocytes by several intracellular signaling molecules
(Figure 2) including janus kinase-signal transducer and activator
FIGURE 1 | Effect of 1,25(OH)2D3 on adipose tissue/lean and obese state. ∗Vitamin D levels (25(OH)D) according to the Institute of Medicine, Food and
Nutrition Board. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academy Press, 2011.
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FIGURE 2 | Overview of 1,25(OH)2D3 on regulating factors in
adipogenesis. 1,25(OH)2D3 has both stimulating and inhibition effect on
adipogenesis. 1,25(OH)2D3 suppress dickkopf1(DKK1) and secreted
frizzled-related protein 2 (SFRP2) expression in mouse bone marrow stromal
cells (BMSCs) there by suppressing adipogenic peroxisome
proliferator-activated receptor γ/retinoid X receptor complex (PPARγ/RXRα)
mediated by stabilization of β-catenin through wingless-type MMTV
integration site family, member 10 (WNT10) inhibition. Furthermore,
1,25(OH)2D3 regulates several adipogenic mediators during differentiation,
proliferation and maturation of mesodermal cells into adipocytes including
CCAAT/enhancer-binding proteins α, β, and γ (C/EBPα, β, and γ), C/EBPβ
corepressor eight twenty-one (ETO), PPARγ/RXRα, fatty acid binding protein
4 (FABP4), lipoprotein lipase (LPL), fatty acid synthase (FASN), stearoyl-coA
desaturase-1 (SCD1), glucose transporter type 4 (GLUT4) and
phosphoenolpyruvate carboxykinase (PEPCK). The arrows in the figure
indicate activation and blunted line indicate inhibition. The red lines and (+/−)
indicate stimulatory or inhibitory effect of 1,25(OH)2D3 on adipogenesis
dependent on the species or cellular systems studied.
of transcription 3 (JAK-STAT3) (Zhang et al., 2011), glutathione
(Vigilanza et al., 2011), SMAD proteins (Jin et al., 2006) and ribo-
somal protein S6 kinase 1 (S6K1) (Carnevalli et al., 2010) affecting
adipogenic transcription factors. In preadipocytes, differentia-
tion factors need to be released from their suppressive signaling
molecules such as members of wingless (WNT) family (Ross
et al., 2000), protein of the retinoblastoma (Rb) family (Scime
et al., 2005), preadipocyte factor 1 (Pref1) (Smas and Sul, 1993)
and Necdin, member of the melanoma-associated antigen fam-
ily of proteins (Fujiwara et al., 2012) to undergo differentiation.
The terminal differentiation to mature adipocytes is regulated
by a number of transcriptional factors including early key reg-
ulator CAAT/enhancer binding proteins (C/EBPβ followed by
C/EBPα, C/EBPδ), the master regulator PPARγ and sterol regu-
latory binding protein 1 (SREBP1) (Payne et al., 2009; White and
Stephens, 2010). These transcriptional factors induce expression
of various genes related to lipogenesis, lipolysis and insulin sen-
sitivity including fatty acid binding protein (FABP4), lipoprotein
lipase (LPL), glucose transporter (GLUT4) and fatty acid synthase
(FASN) (Lefterova et al., 2008; Nielsen et al., 2008; Madsen et al.,
2014).
Investigations of the molecular regulation of 1,25(OH)2D3 on
adipogenesis have been conducted in vitro. In mouse 3T3-L1
preadipocytes, 1,25(OH)2D3 inhibits adipogenesis by acting on
multiple targets suppressing C/EBPα and PPARγ expression,
specifically antagonizing the transacting activity of PPARγ, and
sequestering the nuclear receptor retinoic X receptor (RXR), a
member nuclear receptor superfamily and down regulating both
C/EBP β mRNA expression and C/EBP β nuclear protein levels
(Kong and Li, 2006) (Figure 2). 1,25(OH)2D3 stimulates expres-
sion of the C/EBP β corepressor, eight twenty-one (ETO), and
thus further inhibits the action of any remaining C/EBP β tran-
scriptional effects required for adipogenesis (Blumberg et al.,
2006).
Although early studies have established an inhibitory action of
1,25(OH)2D3 in 3T3-L1 preadipocytes differentiation, recently, a
more specific effect of 1,25(OH)2D3 on WNT signaling emerged.
WNT/β-catenin maintain preadipocytes in their undifferentiated
state and thus preventing adipogenesis (Ross et al., 2000). The
anti-adipogenic effect of 1,25(OH)2D3 is mediated by mainte-
nance of WNT10B and nuclear β-catenin levels expression levels
in 3T3-L1 preadipocytes, thereby suppressing transcription fac-
tor PPARγ (Lee et al., 2012). In addition, 1,25(OH)2D3 also
inhibited mouse bone marrow stromal cells(BMSCs) differen-
tiation into adipocytes by suppression of dickkopf1 (DKK1)
and secreted frizzled-related protein 2 (SFRP2) expression levels
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via VDR mediated WNT signaling (Cianferotti and Demay,
2007).
In contrast, 1,25(OH)2D3 treatment of porcine mesenchymal
stem cells (MSCs) stimulated both proliferation and differen-
tiation in a dose dependent manner toward adipocytic pheno-
type by increasing PPARγ, LPL and adipocyte-binding protein
2 (AP2) mRNA levels (Mahajan and Stahl, 2009). In human
tissue, 1,25(OH)2D3 promotes differentiation of already com-
mitted subcutaneous preadipocytes through increased expres-
sion of adipogenic markers FABP4 and LPL (Nimitphong et al.,
2012). Narvaez et al. (2013) demonstrated that mesenchymal cells
differentiate in the presence of 1,25(OH)2D3 toward adipocytes
with an enhanced lipid accumulation and increased expression of
adipogenic marker genes (FASN, FABP4, and PPARγ).
In conclusion, 1,25(OH)2D3 regulates adipogenesis at various
levels of the entire differentiation process (Figure 2). However,
there are significant differences summarized in Table 1; the
reasons for these differences are not clear at the moment—
methodological differences as well as physiological roles of the
adipose tissue in different species in their environments might
affect these processes. Further studies are needed to address the
effects of vitamin D in adipose tissue and its relevance in the
associated diseases.
VITAMIN D AND ADIPOSE TISSUE INFLAMMATION
In obesity, adipose tissue undergoes hypertrophic enlargement,
which results in an imbalanced blood flow leading to hypoxia,
inflammation and macrophage infiltration (Goossens, 2008;
Trayhurn, 2013). The hypertrophied adipocytes are characterized
by a reduced secretion of adiponectin and increased secretion of
several proinflammatory cytokines such as interleukin IL-6, IL-
8, TNF-α, resistin and MCP1 (Wellen and Hotamisligil, 2003;
Maury and Brichard, 2010; Vlasova et al., 2010).
1,25(OH)2D3 acts at several levels to modulate the function
of the immune system (Lemire, 2000). Several in vitro stud-
ies in the mouse 3T3-L1 cell line and human adipocytes have
demonstrated that 1,25(OH)2D3 inhibits chronic inflammation
in adipose tissue (Table 2). However, earlier studies performed in
3T3-L1 and human adipocytes demonstrate contradictory results
favoring inflammatory cytokine expression (Sun and Zemel,
2008); the reasons for the contradictory findings are unclear.
Recent evidence focuses on the involvement of 1,25(OH)2D3 in
the regulation of adipose tissue inflammation by reducing the
proinflammatory cytokines secreted from adipose tissue.
In differentiated adipocytes from human subcutaneous white
adipose tissue 1,25(OH)2D3 attenuates TNF-α induced MCP-
1 secretion, while it inhibited secretion of adiponectin with-
out affecting its mRNA levels (Lorente-Cebrian et al., 2012).
In human subcutaneous adipose tissue fragments 1,25(OH)2D3
reduced IL-1β induced expression of the inflammatory genes
MCP-1, IL-6 and IL-8. However, results from the cell culture
experiments have not been consistent with the in vivo findings.
In a randomized controlled trial including fifty-five obese sub-
jects, oral supplementation of vitamin D 7000 IU per day over 26
Table 1 | Effect of 1,25(OH)2D3 on adipogenesis in different species.
Species and cell type Effect on adipogenesis References
MOUSE
3T3-L1 preadipocytes Inhibition
- VDR and RXR mediated suppression of C/EBPα, PPARγ,
and C/EBPβ (increased C/EBPβ corepressor ETO)
- Through maintenance of WNT10B and β-catenin levels
Blumberg et al., 2006; Kong
and Li, 2006; Lee et al., 2012
Primary preadipocytes Promotion
- Increasing FABP4, adiponectin and PPARγ
Nimitphong et al., 2012
Mouse bone marrow stromal cells(BMSCs) Inhibition
- Suppression of DKK1 and SFRP2 (WNT suppressors)
Cianferotti and Demay, 2007
PORCINE
Porcine preadipocytes Inhibition
- Inhibition of PPARγ and RXR, down regulated LPL, PEPCK,
GPDH, SCD1, and GLUT4
Zhuang et al., 2007
Porcine mesenchymal stem cells (MSCs) Promotion
- Increased adipogenic markers (PPARγ, LPL AP2)
Mahajan and Stahl, 2009
HUMAN
Subcutaneous preadipocytes Promotion
- Increasing expression (FABP4 and LPL)
Nimitphong et al., 2012
Mesenchymal progenitor cells from human
adipose tissue
Promotion
- Increase of adipogenic marker genes (FASN, FABP, and
PPARγ)
Narvaez et al., 2013
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Table 2 | 1,25(OH)2D3 and inflammation.
Cell type 1,25(OH)2D3 Mechanism of action References
Mouse 3T3-L1 and human adipocytes (differentiated from
subcutaneous preadipocytes)
Increased IL-6 and TNFα in mouse 3T3-L1
Increased IL -6 and IL -8 in human adipocytes
Sun and Zemel, 2007
Mouse 3T3-L1 and human adipocytes (differentiated from
subcutaneous preadipocytes)
Increased CD14, MIF, M-CSF, MIP, TNFα, IL -6, and MCP-1 Sun and Zemel, 2008
Human adipocytes (differentiated from subcutaneous
preadipocytes)
Regulated nearly 140 genes favoring inflammation and
oxidative stress
Sun et al., 2008
Mouse 3T3-L1 and Swiss mice on HFD supplemented
with 1,25(OH)2D3
Reduction of IL -6 in both cell culture medium and tissue
EFP
Lira et al., 2011
Preadipocytes isolated from human subcutaneous WAT Reduction in MCP-1 and adiponectin Lorente-Cebrian et al., 2012
Bone marrow-derived human mesenchymal stem cells
and mature adipocytes from subcutaneous adipose tissue
Reduction in IL -6 and inhibited NF-κB nuclear
translocation
Mutt et al., 2012
Mouse 3T3-L1 and human preadipocytes Decreased IL -6, MCP-1, IL -1β and inactivation of NF-κB
by inducing IκBα, decreased p38 phosphorylation
Marcotorchino et al., 2012
Human subcutaneous adipose tissue fragments Reduction in MCP-1, IL -6, and IL -8. Wamberg et al., 2013
Human preadipocytes Reduction in MCP-1, IL -8 and IL -6 and inactivation of
NF-κB by upregulation of IκBα
Gao et al., 2013
Human preadipocytes differentiated to mature adipocytes Reduction in MCP1, IL -8, RANTES, IL -6 and IL -1β
Increased IκBα levels and reduced NF-κB p65
phosphorylation results in inhibition of NF-κB
Decreased phosphorylated p38 MAPK
Ding et al., 2013a,b
weeks did neither affect inflammation markers in the circulation
nor in the adipose tissue (Wamberg et al., 2013). In mice on high
fat diet, dietary supplementation of 1,25(OH)2D3 (0.05mg/kg of
diet) reduced their IL-6 protein content in epididymal adipose
tissue and in the 3T3-L1 cell line stimulated by LPS (Lira et al.,
2011).
Signal transduction of inflammatory pathways in adi-
pose tissue involves activation of NF-κB and transloca-
tion of p65 to nucleus mediated by degradation of IκBα
(Tourniaire et al., 2013). Mutt et al. (2012) have demonstrated
that, 1,25(OH)2D3 suppressed LPS-stimulated IL-6 secretion in
human isolated mature and MSC differentiated adipocytes. This
was confirmed byMarcotorchino et al. (2012), who demonstrated
that 1,25(OH)2D3 inhibits the inflammatory markers in both
mouse and human adipocytes via the involvement of p38 MAP
kinase and NF-κB classical inflammatory pathway and later by
Gao et al. (2013) and Ding et al. (2013a).
In summary, the presence of 1,25(OH)2D3 inhibited
chemokine and cytokine secretion in human adipocytes.
1,25(OH)2D3 strongly inhibited the activation of the NF-κB and
MAPK signaling pathways, which prevent gene transcription of
the proinflammatory factors (Figure 3). 1,25(OH)2D3 has been
shown by different groups in different models to significantly
reduce inflammation in the adipose tissue. However, further
studies are needed to provide more evidence for the physiological
relevance and the concentration levels of active 1,25(OH)2D3 in
lean and obese subjects required to ameliorate the inflammation
and associated complications.
VITAMIN D AND ADIPOSE TISSUE ENERGY HOMEOSTASIS
The discovery of VDR expression in adipocytes was the corner-
stone for the investigations of the effect of vitamin D on adipose
tissue beyond its role in bone metabolism (Stumpf, 1995; Ding
et al., 2012). Recent findings in genetically modified mouse mod-
els highlighted a new role for vitamin D and its receptor VDR
in adipose tissue energy homeostasis. VDR knockout (VDR−/−)
mice had reduced body weight and lower serum leptin con-
centrations, despite of an increased compensatory food intake
compared to wild type mice of different genetic background
C57BL6 and CD1. VDR−/− mice were highly resistant to high
fat diet induced weight gain (Narvaez et al., 2009). In addi-
tion, these mice are characterized by a relatively short lifespan,
alopecia, osteoporosis, ectopic calcification, progressive loss of
hearing and balance (Keisala et al., 2009; Tuohimaa, 2009). Mice
lacking CYP27B1 [the (25(OH)D)-1α-hydroxylase enzyme, con-
verts 25(OH)D3 in to 1,25(OH)2D3], displayed features similar to
VDR−/− with reduced body weight, hypoleptinemia and hyper-
phagia. Interestingly, uncoupling protein 1 (UCP-1) expression in
white adipose tissue of the VDR−/− mice was increased 25-fold.
In addition to reduced body weight, VDR−/− mice had less
body fat and lower levels of plasma triglycerides and cholesterol
in comparison to the wild type counterparts even though mice
were challenged with a high fat diet (Wong et al., 2009; Weber and
Erben, 2013). The depletion of adipose tissue in younger VDR−/−
mice progresses with aging and resulted in severe mammary adi-
pose tissue atrophy, along with the increased respiration and
energy expenditure (Welsh et al., 2011). The effect on plasma lipid
profile and unaltered food intake in these mice was confirmed
by an increased β-oxidation rate in isolated adipocytes medi-
ated by the induction of carnitine palmitoyltransferase II (CPTII)
(Figure 3). VDR−/− mice had an increased basal metabolism
demonstrated by the total energy expenditure, oxygen consump-
tion and CO2 production in comparison with the wild type mice
(Wong et al., 2009). In addition, UCP1, UCP2, and UCP3mRNAs
were upregulated in brown adipose tissue of the VDR−/− mice
fed high fat diet. In contrast to VDR knock out models with the
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FIGURE 3 | Molecular actions of 1,25(OH)2D3 in inflammation and
energy homeostasis in adipocytes. Stimulation via e.g.,
lipopolysaccharide (LPS), TNF-α via specific receptors e.g., Toll like receptor
(TLR), IL-6 receptors (IL-6R) activate Nuclear factor kappa-B (NFκB) or p38
mitogen-activated protein kinase (P38MAPK) signaling dependent
transcription of inflammatory genes such as interleukin 6 (IL-6), tumor
necrosis factor alpha (TNF-α) and interleukin 1 beta (IL-1β). 1,25(OH)2D3
inhibits inflammation by inhibiting Inhibitor kappa-B (IκBα) phosphorylation
and translocation of NFκB as well P38MAPK into the nucleus.
Furthermore, 1,25(OH)2D3 affects energy homeostasis. VDR−/− mice
increases energy expenditure through uncoupling proteins (UCPs). The
arrows in the figure indicate activation and blunted line indicate inhibition.
The red lines and arrows indicate the effect of 1,25(OH)2D3 on
inflammatory signaling pathway.
ablation of the receptor in the whole animal, adipose tissue spe-
cific overexpression of human VDR via the adipocyte fatty acid
binding protein (aP2) promoter/enhancer element resulted in a
decreased energy expenditure and oxygen consumption and thus
the mice had an increased body weight and fat mass (Wong et al.,
2011).
In conclusion, these transgenic animal models indicate a crit-
ical and complex role for 1,25(OH)2D3 and VDR signaling
in energy homeostasis. However, notwithstanding the cell and
mouse studies, further studies need to explore the role of vitamin
D on human adipose tissue metabolism in vivo.
GENETIC VIEW ON THE ACTIONS OF VDR IN ADIPOCYTES:
INTEGRATIONWITH OTHER TISSUES
The VDR genomic interactions in different types of cells and tis-
sues have been mapped by in vitro experiments where target cells
(primary or secondary) have been treated with 1,25(OH)2D3.
Upon stimulation of VDR by its ligand, it forms a heterodimer
with RXR and subsequently binds to the vitamin D response ele-
ments (VDREs) within the regulatory regions of target genes. The
abundance of VDR binding sites and the regulation of changes
in gene expressions are analyzed using array technology and
the combination of chromatin immunoprecipitation (ChIP) with
massive parallel sequencing (ChIP-seq). These advanced tech-
niques have provided novel mechanistic insights of 1,25(OH)2D3
action via VDR in the regulation of cellular metabolism and dis-
ease states. However, studies on genome-wide actions of VDR in
adipocytes are sparse.
Recent microarray studies of human adipocytes and
preadipocytes incubated with macrophage-conditioned medium
derived from U937 monocytes, confirmed the induction of genes
associated with the metabolism and action of 1,25(OH)2D3,
including CYP27B1 and VDR (Trayhurn et al., 2011). An earlier
single microarray study in human subcutaneous adipose tissue
derived preadipocytes differentiated to adipocytes demonstrated
237 1,25(OH)2D3 responsive genes (cell proliferation, angiogen-
esis, cell cycle, inflammation and response to oxidative stress)
(Sun et al., 2008).
Most recent studies in the other cell types such as mono-
cytes, primary CD4+ T-lymphocytes, adenocarcinoma, hepatic
stellate and lymphoblastoid cell lines (LCLs) (Ramagopalan et al.,
2010; Heikkinen et al., 2011; Meyer et al., 2012; Ding et al.,
2013b; Handel et al., 2013; Tuoresmäki et al., 2014) contribute
to a systemic understanding of 1,25(OH)2D3 induced gene reg-
ulation. Depending on the cell type, concentration and length
of 1,25(OH)2D3 incubation approximately 2000VDR genomic
binding sites have been found in these studies. Yet, alterations in
DNA accessibility in cell lines after short-term stimulation with
1,25(OH)2D3 may not reflect the physiological 1,25(OH)2D3
levels in vivo due to the different tissue environment and
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sympathetic influence. In primary CD4+ lymphocyte cells,
isolated from nine healthy individuals with measured serum
25(OH)D levels, VDR binding sites ranged from 200 to 7118
across the genome and the corresponding 25(OH)D levels directly
correlated with the number of VDR binding sites, suggesting far
greater number of VDR binding sites in 1,25(OH)2D3 sufficient
than the insufficient subjects (Handel et al., 2013).
Genome-wide VDR cistromes are not available in adipocytes,
but recent VDR binding sites in other cell types has been mapped
with ChIP-seq from both upstream and downstream of the tran-
scription start site. Further genome wide view actions of VDR in
adipocytes as well as integration of other tissue specific cell types
are warranted.
CONCLUSION AND FUTURE DIRECTIONS
Adipose tissue acts in addition to nutrient storage as an active
endocrine organ. In the obese state, sub-clinical inflammation
increases the risk of a variety of chronic diseases. Vitamin D defi-
ciency is common in overweight and obese individuals, and it
is possible that lower circulating concentrations may contribute
to increases in metabolic risk. A genome-wide association study
of 25(OH)D concentrations in 33996 individuals of European
descent from 15 cohorts found variants near genes involved in
cholesterol synthesis, hydroxylation, and vitamin D transport
affect vitamin D status (Wang et al., 2010). Genetic variation at
these loci identifies individuals who have a substantially increased
risk of vitamin D insufficiency.
On the cellular level, 1,25(OH)2D3 has a significant role in
adipogenesis and inflammation which might be species depen-
dent. Holick et al. (1989) demonstrated that the peak circulat-
ing concentrations of 25(OH)D in the elderly are about 30%
of that of the young. These findings suggest that there will
be significant challenges in the translation of the finding from
models and non-human primates to the targeted human pop-
ulations (healthy, diseased, black, white, age, BMI, geograph-
ical latitude, race). More evidence accumulates that one dose
does not fit all (Powe et al., 2014). Powe and colleagues eval-
uated vitamin D binding proteins (VDBP) and 25(OH)D lev-
els in black and white Americans. Black adult Americans had
low 25(OH)D levels and with the threshold of 20 or 30 ng/ml,
77–96% of them would be classified as vitamin D deficient.
Surprisingly, the black study participants had higher bone min-
eral density, higher calcium levels and only slightly higher
parathyroid levels than the white study participants due to VDBP
gene polymorphisms (rs7041 and rs4588). The authors spec-
ulated that the low levels of VDBP might protect against the
adverse effects of vitamin D deficiency. Sufficient levels of this
essential hormone and the development of potent novel vita-
min D receptor analogs (Peräkylä et al., 2005; Leyssens et al.,
2014), which could be easily and cheaply substituted, are bene-
ficial in the maintenance of health and prevention of a number
of diseases associated with vitamin D deficiency. Recent sys-
temic review and meta-analysis summary of observational stud-
ies and randomized interventions investigated the association
between the circulating 25(OH)D concentrations and cause spe-
cific mortality in 900,000 subjects in 26 countries (Chowdhury
et al., 2014). There was an inverse association of mortality
risk and vitamin D levels, yet the observed association could
be direct [suboptimal 25(OH)D concentrations] or indirect
through higher BMI or disadvantageous social circumstances.
Thus, prospective intervention studies are needed to establish
potential causal associations between vitamin D levels and disease
outcomes.
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